ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

DuPont And Caribou Cross-License CRISPR

by Michael McCoy
October 12, 2015 | APPEARED IN VOLUME 93, ISSUE 40

DuPont and the biotech firm Caribou Biosciences have agreed to cross-license their intellectual property related to the new gene-editing tool called CRISPR/Cas. Caribou was founded in 2011 by CRISPR research pioneer Jennifer Doudna of the University of California, Berkeley, and colleagues. DuPont obtained its technology in June through a license from Vilnius University. DuPont made an equity investment in Caribou as part of the biotech firm’s recent Series A funding round. The two firms also will collaborate on research.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment